Clonazepam Tapering Protocol

Monitoring and Management

Assess for withdrawal symptoms after each dose reduction before proceeding to the next step, as recommended by the guideline society, with a strength of evidence not specified 1, 2
If withdrawal symptoms become severe, return to the previous well-tolerated dose and slow the taper further, according to the guideline society, with a strength of evidence not specified 1

For autonomic symptoms (sweating, tachycardia): Consider α2-adrenergic agonists like clonidine, as suggested by the Mayo Clinic, with a strength of evidence not specified 3, 1
For insomnia: Consider short-term, non-benzodiazepine sleep aids, as recommended by the guideline society, with a strength of evidence not specified 1
For muscle aches and pain: Acetaminophen or NSAIDs may be beneficial, according to the Mayo Clinic, with a strength of evidence not specified 3
Incorporate non-pharmacological approaches such as cognitive behavioral therapy and stress management techniques, as recommended by the guideline society, with a strength of evidence not specified 1, 2

For patients who have been on clonazepam for more than 1 year, consider an even slower taper of 10% per month, as recommended by the guideline society, with a strength of evidence not specified 1, 2
Never abruptly discontinue clonazepam except in cases of serious medical toxicity, as recommended by the guideline society, with a strength of evidence not specified 1
If the patient is also taking opioids, prioritize tapering the benzodiazepine first due to the risk of fatal respiratory depression from concurrent use, as recommended by the CDC, with a strength of evidence not specified 4
Patients with a history of seizures require particularly careful monitoring during the taper, as recommended by the guideline society, with a strength of evidence not specified 2

Avoid tapering too quickly, which increases risk of withdrawal symptoms and relapse, as recommended by the guideline society, with a strength of evidence not specified 1
Avoid setting arbitrary time limits for completing the taper; individualize based on patient response, as recommended by the guideline society, with a strength of evidence not specified 1

Monitor patients at least monthly during the tapering process, as recommended by the guideline society, with a strength of evidence not specified 1, 2
Provide education about increased risk of withdrawal symptoms if returning to previous doses, as recommended by the guideline society, with a strength of evidence not specified 2
Screen for anxiety, depression, and substance use disorders that may emerge during tapering, as recommended by the guideline society, with a strength of evidence not specified 2